What to know before paying for joint care

Bring the details that help the exam

Note when you first felt sore and what makes the ache better or worse. Bring a list of your pills plus any old X-ray or scan reports. Tell the provider about falls, past operations, and swelling. Explain which activity you hope to regain. Those facts help separate common wear from a tendon problem or fresh injury. They can also show when soreness may be coming from the back. Don't try to guess the diagnosis before the exam.

A few clear details give the provider useful facts.

Ask what the visit is meant to decide

The provider will watch how you move and check strength, motion, and tender areas. A scan may be reviewed when it could change the choice. Ask what the exam found in plain words. Regenerative treatment means non-surgical care that uses body material, such as blood. PRP, short for platelet-rich plasma, starts with blood drawn and spun at the clinic. If either comes up, ask about likely relief, time away from normal tasks, cost, and return care.

You can take the written plan home before deciding.

Know when the plan needs another look

Be careful when every sore joint gets the same answer. Exact success claims need solid medical support. Good care explains its limits and names another choice if relief isn't enough. The clinic shouldn't rush you with a price that ends that day. Ask who will handle a problem after the visit. Also ask which symptoms mean you need to call. If an answer stays unclear, take more time before paying.

Plain answers matter more than a long list of treatment names.

Sources

1. The ESSKA-ORBIT European consensus on blood-derived orthobiologics graded 28 question-statement sets; only 9 of 28 had high-level scientific support. Three statements reached grade A: that there is enough preclinical and clinical evidence to support PRP use in knee OA; that clinical evidence shows effectiveness in MILD TO MODERATE knee OA (KL grade 3 or lower); and that PRP provides a longer effect than the short-term effect of corticosteroid with a safer profile. The panel regarded PRP as a valid and possible first-line injectable option for KL grades 1-3.

   Laver L, et al. — The use of injectable orthobiologics for knee osteoarthritis: A European ESSKA-ORBIT consensus. Part 1-Blood-derived products (platelet-rich plasma).. Knee Surgery, Sports Traumatology, Arthroscopy, 2024. DOI: 10.1002/ksa.12077.

2. FDA's July 2020 final guidance 'Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use' is the document that decides whether a given orthobiologic can be used without a licence: an HCT/P may be regulated solely under section 361 only if it is minimally manipulated AND intended for homologous use, among other criteria; otherwise it is a drug or biological product requiring an approved licence or an active investigational new drug application.

   U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and Food and Drug Administration Staff. FDA Guidance Document, 2020.

3. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

4. FDA's consumer page on regenerative medicine tells patients to confirm that a product is either FDA-approved or being studied under an Investigational New Drug application before agreeing to treatment, and warns that unapproved regenerative-medicine products carry real safety risks.

   U.S. Food and Drug Administration — Important Patient and Consumer Information About Regenerative Medicine Therapies. U.S. Food and Drug Administration, 2024.

5. A qualitative study interviewing 38 patients and 19 primary care clinicians found patients valued injections as an alternative to treatments they found undesirable, but reported wide variation in access, in onset and in how long the effect lasted; clinicians described an overarching theme of 'caution and competence', including uncertainty about the evidence and guidelines and the possibility of placebo.

   Moore AJ, et al. — Intra-articular corticosteroid injections for osteoarthritis: A qualitative study of patients' and clinicians' experiences.. PLoS One, 2024. DOI: 10.1371/journal.pone.0311668.